What GLP-1 drugs does Eli Lilly offer?

Eli Lilly offers Mounjaro (for diabetes), Zepbound (for obesity), and Foundayo (a combination for diabetes and obesity).

How do GLP-1 drugs impact Eli Lilly's growth?

GLP-1 drugs are the main growth driver for Eli Lilly in 2026, thanks to rising demand in diabetes and obesity markets.

Who are Eli Lilly's competitors in the GLP-1 market?

The main competitor is Novo Nordisk with Ozempic and Wegovy.

Foundayo is a combination drug of tirzepatide and another agent, aiming to improve outcomes for patients with both diabetes and obesity.

Eli Lilly's GLP-1 Portfolio Drives Growth in 2026

Eli Lilly (LLY) is sustaining growth in 2026 through its GLP-1 portfolio, with Mounjaro, Zepbound, and Foundayo gaining traction in obesity, diabetes, and related markets.

Eli Lilly (NYSE: LLY) continues to post strong growth in 2026, driven by its GLP-1 portfolio. According to a report from Zacks, Mounjaro, Zepbound, and Foundayo are gaining increasing traction in the obesity, diabetes, and related markets.

GLP-1 Drugs: The Growth Engine

GLP-1 receptor agonists are a key class of drugs for type 2 diabetes and weight management. Mounjaro (tirzepatide), Zepbound (tirzepatide for obesity), and Foundayo (a combination of tirzepatide and another agent) are central to Lilly's strategy.

Mounjaro

Mounjaro, approved by the FDA for type 2 diabetes, has shown high efficacy in lowering blood sugar and weight.

Zepbound

Zepbound, the same compound (tirzepatide) at different doses, is approved for obesity and has seen high demand.

Foundayo

Foundayo is a combination drug targeting improved outcomes in patients with both diabetes and obesity.

Competitive Landscape

Lilly faces strong competition from Novo Nordisk, which markets Ozempic and Wegovy. However, Lilly's diversified portfolio may provide a competitive edge.

What It Means for Investors

Eli Lilly appears well-positioned to continue growing thanks to its strong GLP-1 portfolio. However, investors should monitor competition, regulatory developments, and pricing. This article does not constitute a buy or sell recommendation.